Since its creation in 1995, ALBOMED became one of the European leaders in the development and commercialization of hyaluronic acid injectable products for ophthalmic and orthopaedic products.

The company is continuously investing in product development to provide doctors with safe and high-quality products for outstanding outcomes.

In 2022, ALBOMED launched INNORYOS - a German engineered technology designed to maximize the relief of osteoarthritis patients.